• Richard Sullivan has been named president and CEO of Interface Biologics (Toronto). He has more than 30 years of senior management and executive experience in the life sciences industry, most recently as CEO of Atlantis Components and prior to that as chief operating officer of Catheter Innovations. Interface Biologics is a therapeutic biomaterials company focused on producing the next generation of bioresponsive polymers for implantable cardiovascular and urogenital medical devices.

• Walter Maupay Jr. has been appointed chairman of the board of Kensey Nash (Exton, Pennsylvania). Maupay has served on the company’s board since 1995. Prior to his retirement in 1995, he was a group executive with Bristol-Myers Squibb and president of Calgon Vestal Laboratories. Kensey Nash is a manufacturer of absorbable biomaterials-based products with applications in the cardiology, orthopedics, spine, drug and biologics delivery, periodontal/dental, surgical and wound care markets.

• Christopher Delporte, Washington editor for Cardiovascular Device Update, has joined the Medical Device Manufacturers Association (Washington) as director of member relations and communications. Prior to taking the CDU post in Washington in the spring of 2004, Delporte was a managing editor with Thomson American Health Consultants in Atlanta, editing and writing newsletters on topics ranging from hospital admitting to medical ethics. He has 10 years of journalism and communications experience.

• David Steinhaus, MD, has been named vice president and medical director of the cardiac rhythm management division of Medtronic (Minneapolis), effective Oct. 14. In taking the position at Medtronic, Steinhaus will leave his position as head of the Mid America Heart Institute at St. Luke’s Health System (Kansas City, Missouri) and as president and executive medical director of Cardiovascular Consultants PC, a medical practice of 30 doctors who direct the Mid America Heart Institute. Steinhaus has worked at Cardiovascular Consultants and the Mid America Heart Institute for 21 years. The practice operates the only heart transplant program in the region.

OmniSonics Medical Technologies (Wilmington, Massachusetts), developer of the Resolution Endovascular System, reported three executive appointments. Maximillian Fiore has been named senior vice president, research and development and operations; Doug Hutchison has been named vice president, marketing; and Brian Connor has been named vice president, product development. Previously, Fiore was vice president of research and development at Smith & Nephew Endoscopy. Hutchison previously was global marketing director for Medtronic Endovascular Innovations. Connor most recently was director of R&D at HydroCision. OmniSonics says that its OmniWave Technology is the first technology that enables the delivery of acoustic energy over the active length of a small-diameter wire, with applications for treating peripheral and coronary vascular occlusive conditions.

• John Hoffer has joined SyntheMed (Oceanport, New Jersey) in the newly created position of director of quality systems and regulatory affairs. He joins the company from the Medical Products division of BOC Gases, where he served as director of regulatory compliance and quality assurance. SyntheMed is a biomaterials company engaged in the development and commercialization of anti-adhesion and drug-delivery products lead product, Repel-CV Adhesion Barrier, is designed for use in cardiac surgery.